Archive for News Report

Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases

February 26, 2026

Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+

February 26, 2026

Boehringer bets up to $500m on Sitryx immunology programme

February 26, 2026

Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program

February 26, 2026

Evommune’s Dupixent-like phase 2 eczema data drive 75% stock rally

February 11, 2026

Mediar gains $76M for clinical trials of three fibrosis drugs

January 7, 2026